Biotech

All Articles

Bicara, Zenas seek IPOs to drive late-phase assets toward market

.Bicara Therapeutics and also Zenas Biopharma have actually offered clean motivation to the IPO mark...

Genentech to finalize cancer immunology analysis team

.Genentech will definitely shut its cancer cells immunology analysis department, and system mind and...

Kezar falls sound lump yet to prove its own worth in phase 1 trial

.Kezar Life Sciences is falling its own dim phase 1 strong growth drug as the biotech goes all-in on...

Acelyrin loses izokibep, lays off 3rd of staff

.Even with izokibep sustaining its own newly found winning streak in the medical clinic, Acelyrin is...

Rivus' phase 2 obesity-related cardiac arrest test strikes endpoint

.Rivus Pharmaceuticals has actually plumped up the customers of its own fat-busting, muscle-sparing ...

Ovid halts preclinical work, IV plan after soticlestat fall short

.Ovid Therapeutics currently disclosed final month that it was actually trimming back its head count...

Eli Lilly opens $700M nucleic acid R&ampD center in Boston ma Seaport

.Eli Lilly has opened up a $700 thousand R&ampD center in the Boston Port, enhancing its own RNA and...

Boundless Bio creates 'small' cutbacks 5 months after $100M IPO

.Just 5 months after safeguarding a $100 thousand IPO, Limitless Bio is actually already laying off ...

Halda's $126M will certainly advance 'keep and kill' lump medicines

.The preliminary phases of oncology R&ampD aren't except interesting new methods, and Halda Therapeu...

Lykos 'remorses' not divulging research offenses along with author

.Psychopharmacology has actually taken 3 articles regarding midstage scientific test records analyzi...